The FDA has approved Reclast (zoledronic acid, from Novartis) injection for the prevention of osteoporosis in women for two years with a single dose.  This approval was based on a study involving more than 500 postmenopausal women with osteopenia, or low bone mass. Reclast significantly increased lumbar spine BMD relative to placebo at the end of the two-year study.

Reclast is already approved for the treatment of postmenopausal osteoporosis; to reduce the incidence of new clinical fractures in patients at high risk of fractures; Paget’s disease of bone (men and women); and the treatment and prevention of glucocorticoid-induced osteoporosis in men and women expected to be on glucocorticoids for at least 12 months.

For more information call (866) RECLAST or visit www.reclast.com.